Search research articles
Contact Us
Filters
Showing results (161-170 of 289) with videos related to
Page
of 29
Sort By:
Emerging Infectious Diseases
|
July 27, 2002
Outbreak of cyclosporiasis associated with imported raspberries, Philadelphia, Pennsylvania, 2000
Alice Y Ho, Adriana S Lopez, Michael G Eberhart, et al.
Muscle & Nerve
|
July 30, 2013
The motor neuron response to SMN1 deficiency in spinal muscular atrophy
Peter B Kang, Clifton L Gooch, Michael P McDermott, et al.
Annals of Clinical and Translational Neurology
|
May 14, 2022
Scientific rationale for a higher dose of nusinersen
Richard S Finkel, Monique M Ryan, Samuel Ignacio Pascual Pascual, et al.
Annals of Neurology
|
April 24, 2012
Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability
Joshua Burns, Robert Ouvrier, Tim Estilow, et al.
Orphanet Journal of Rare Diseases
|
April 7, 2020
Longitudinal natural history of type I spinal muscular atrophy: a critical review
Eugenio Mercuri, Simona Lucibello, Marco Perulli, et al.
Lancet (London, England)
|
April 25, 2015
Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial
Gunnar M Buyse, Thomas Voit, Ulrike Schara, et al.
Plos Pathogens
|
February 24, 2012
Portrait of Candida albicans adherence regulators
Jonathan S Finkel, Wenjie Xu, David Huang, et al.
Neurology
|
April 5, 2013
Severe congenital RYR1-associated myopathy: the expanding clinicopathologic and genetic spectrum
Diana Xerxes Bharucha-Goebel, Mariarita Santi, Livija Medne, et al.
Journal of the Peripheral Nervous System : JPNS
|
June 21, 2013
Transitioning outcome measures: relationship between the CMTPedS and CMTNSv2 in children, adolescents, and young adults with Charcot-Marie-Tooth disease
Joshua Burns, Manoj Menezes, Richard S Finkel, et al.
The Journal of Clinical Investigation
|
September 16, 2025
Open-label phase IV trial evaluating nusinersen after onasemnogene abeparvovec in children with spinal muscular atrophy
Crystal M Proud, Richard S Finkel, Julie A Parsons, et al.
Page
of 29
Search research articles
Search
Showing results (161-170 of 289) with videos related to
Sort By:
Page
of 29
Emerging Infectious Diseases
|
July 27, 2002
Outbreak of cyclosporiasis associated with imported raspberries, Philadelphia, Pennsylvania, 2000
Alice Y Ho, Adriana S Lopez, Michael G Eberhart, et al.
Muscle & Nerve
|
July 30, 2013
The motor neuron response to SMN1 deficiency in spinal muscular atrophy
Peter B Kang, Clifton L Gooch, Michael P McDermott, et al.
Annals of Clinical and Translational Neurology
|
May 14, 2022
Scientific rationale for a higher dose of nusinersen
Richard S Finkel, Monique M Ryan, Samuel Ignacio Pascual Pascual, et al.
Annals of Neurology
|
April 24, 2012
Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability
Joshua Burns, Robert Ouvrier, Tim Estilow, et al.
Orphanet Journal of Rare Diseases
|
April 7, 2020
Longitudinal natural history of type I spinal muscular atrophy: a critical review
Eugenio Mercuri, Simona Lucibello, Marco Perulli, et al.
Lancet (London, England)
|
April 25, 2015
Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial
Gunnar M Buyse, Thomas Voit, Ulrike Schara, et al.
Plos Pathogens
|
February 24, 2012
Portrait of Candida albicans adherence regulators
Jonathan S Finkel, Wenjie Xu, David Huang, et al.
Neurology
|
April 5, 2013
Severe congenital RYR1-associated myopathy: the expanding clinicopathologic and genetic spectrum
Diana Xerxes Bharucha-Goebel, Mariarita Santi, Livija Medne, et al.
Journal of the Peripheral Nervous System : JPNS
|
June 21, 2013
Transitioning outcome measures: relationship between the CMTPedS and CMTNSv2 in children, adolescents, and young adults with Charcot-Marie-Tooth disease
Joshua Burns, Manoj Menezes, Richard S Finkel, et al.
The Journal of Clinical Investigation
|
September 16, 2025
Open-label phase IV trial evaluating nusinersen after onasemnogene abeparvovec in children with spinal muscular atrophy
Crystal M Proud, Richard S Finkel, Julie A Parsons, et al.
Page
of 29